SCHEMBL23534270

SCHEMBL23534270

C=COc1cc(C(=O)OC)ccc1Br

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 2/20 0.51
▸ MAPT P10636 4/20 0.46
▸ CA1 P00915 3/20 0.45
▸ CA2 P00918 3/20 0.45
▸ CA12 O43570 2/20 0.45
▸ CA7 P43166 2/20 0.45
▸ CA9 Q16790 2/20 0.45
▸ CA14 Q9ULX7 2/20 0.45
▸ XDH P47989 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ HSD17B10 Q99714 3/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ HPGD P15428 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ LMNA P02545 2/20 0.44
▸ TP53 P04637 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ ALOX12 P18054 1/20 0.44
▸ HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16545194 0.88 NOTUM (0.55) NOTUMMAPTCA1CA2CA12
SCHEMBL16533400 0.83 MAPT (0.64) MAPTCA1CA2CA12CA7
SCHEMBL24984699 0.83 MAPT (0.64) MAPTCA1CA2CA12CA7
SCHEMBL28754230 0.82 CA12 (0.44) MAPTCA1CA2CA12CA7
SCHEMBL289503 0.82 CA1 (0.44) NOTUMMAPTCA1CA2CA12
SCHEMBL426745 0.82 MAPT (0.62) NOTUMMAPTCA1CA2CA12
SCHEMBL31321821 0.81 KDM4E (0.52) NOTUMMAPTCA1CA2CA12
SCHEMBL22032196 0.81 KDM4E (0.52) NOTUMMAPTCA1CA2CA12
SCHEMBL978911 0.79 NOTUM (0.53) NOTUMMAPTCA1CA2CA12
SCHEMBL16533268 0.78 KMT2A (0.51) NOTUMMAPTCA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4076460-B1 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER MERCK SHARP & DOHME LLC (US) 2026-01-21 — — EP disclosed
US-12441730-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2025-10-14 — — US disclosed
CN-114634512-B Compounds as inhibitors of bruton's tyrosine kinase, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2023-11-14 — — CN disclosed
US-20230114091-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-04-13 — — US disclosed
EP-4076460-A1 PRMT5 INHIBITORS Merck Sharp & Dohme LLC (US) 2022-10-26 — — EP disclosed
CN-114634512-A Compound as Bruton's tyrosine kinase inhibitor, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2022-06-17 — — CN disclosed
WO-2021126729-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-06-24 — — WO disclosed
WO-2021126729-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230114091-A1 PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 NOTUM 1859/4885MAPT 4571/4885CA1 3927/4885
US-12441730-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT3 NOTUM 1859/4885MAPT 4571/4885CA1 3927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback